http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1928498-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b0a0020b4275768296005437c6d61d3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2006-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e47801ba4553c79ef13ffa675f70b52d |
| publicationDate | 2008-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1928498-A2 |
| titleOfInvention | Methods to treat t-cell disorders using tisf |
| abstract | T4 Immune Stimulating Factor (TISF) selectively induces aberrant T-cells to initiate apoptosis. TISF and peptides that are related to TiSF (TISF peptides) are therefore useful for the treatment of disorders characterized by aberrant production, development, or activity of T- cells or other cells of hematopoietic origin. This invention relates to methods of using TISF or a TISF peptide to treat such conditions, compositions containing TISF or a TISF peptide for use in such treatments, and use of TISF or a TISF peptide for the manufacture of pharmaceuticals . |
| priorityDate | 2005-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.